E
Emmanuel A. Burdmann
Researcher at University of São Paulo
Publications - 223
Citations - 15266
Emmanuel A. Burdmann is an academic researcher from University of São Paulo. The author has contributed to research in topics: Acute kidney injury & Nephrotoxicity. The author has an hindex of 49, co-authored 210 publications receiving 13025 citations. Previous affiliations of Emmanuel A. Burdmann include American Society of Nephrology & Hospital de Base.
Papers
More filters
Journal ArticleDOI
Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury
John A. Kellum,Norbert Lameire,Peter Aspelin,Rashad S. Barsoum,Emmanuel A. Burdmann,Stuart L. Goldstein,Charles A. Herzog,Michael Joannidis,Andreas Kribben,Andrew S. Levey,Alison M. MacLeod,Ravindra L. Mehta,Patrick T. Murray,Saraladevi Naicker,Steven M. Opal,Franz Schaefer,Miet Schetz,Shigehiko Uchino +17 more
Journal ArticleDOI
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more
TL;DR: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event ordeath or a renal event) and was associated with an increased risk of stroke.
Journal ArticleDOI
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology
Ravindra L. Mehta,Jorge Cerdá,Emmanuel A. Burdmann,Marcello Tonelli,Guillermo Garcia-Garcia,Vivekanand Jha,Paweena Susantitaphong,Paweena Susantitaphong,Michael V. Rocco,Raymond Vanholder,Mehmet Sukru Sever,Dinna N. Cruz,Bertrand L. Jaber,Norbert Lameire,Raúl Lombardi,Andrew Lewington,John Feehally,Fredric O. Finkelstein,Nathan W. Levin,Neesh Pannu,Bernadette Thomas,Eliah Aronoff-Spencer,Giuseppe Remuzzi +22 more
TL;DR: The ability to provide lifesaving treatments for AKI provides a compelling argument to consider therapy forAKI as much of a basic right as it is to give antiretroviral drugs to treat HIV in low-resource regions, especially because care needs only be given for a Published Online March 13, 2015 http://dx.doi.org/10.1016/ S0140-6736(15)60126-X
Journal ArticleDOI
Erythropoietic response and outcomes in kidney disease and type 2 diabetes
Scott D. Solomon,Hajime Uno,Eldrin F. Lewis,Kai-Uwe Eckardt,Julie Lin,Emmanuel A. Burdmann,Dick de Zeeuw,Peter Ivanovich,Andrew S. Levey,Patrick S. Parfrey,Giuseppe Remuzzi,Ajay K. Singh,Robert D. Toto,Fannie Huang,Jerome Rossert,John J.V. McMurray,Marc A. Pfeffer +16 more
TL;DR: A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels.
Journal ArticleDOI
Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study
Ravindra L. Mehta,Emmanuel A. Burdmann,Jorge Cerdá,John Feehally,Fredric O. Finkelstein,Guillermo Garcia-Garcia,Mélanie Godin,Vivekanand Jha,Norbert Lameire,Nathan W. Levin,Andrew Lewington,Raúl Lombardi,Etienne Macedo,Michael V. Rocco,Eliah Aronoff-Spencer,Marcello Tonelli,Jing Zhang,Giuseppe Remuzzi,Giuseppe Remuzzi +18 more
TL;DR: Common aetiological factors across all countries are identified, which might be amenable to a standardised approach for early recognition and treatment of acute kidney injury.